ZOUBOULIS, C. C.; OKUN, M. M.; GNIADECKI, R.; FOLEY, P. A.; LYNDE, C.; WEISMAN, J.; KARUNARATNE, P.; WILLIAMS, D. A. Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 1, n. 3.1, p. s128, 2017. DOI: 10.25251/skin.1.supp.127. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/81. Acesso em: 23 jul. 2024.